Identifying COVID ‐19 Disease Severity in Real‐World Data: Implications for Medical Product Effectiveness Studies
Pharmacoepidemiology and Drug Safety · 2026
DOI: 10.1002/pds.70363 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von Mayura U Shinde und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Severity of Illness Index, COVID-19, Algorithms, COVID-19 Drug Treatment. Die Arbeit nennt 19 Literaturangaben. Gefördert von: U.S. Food and Drug Administration.
Abstract (Originalsprache)
Purpose
The U.S. Food and Drug Administration (FDA) defined disease severity criteria to assist clinical development of medical products for management of COVID‐19. These definitions were translated to code‐based algorithms for use in real‐world data. We validated the algorithms' performance in ambulatory settings at three regional integrated healthcare delivery systems contributing data to FDA's Sentinel System.
Methods
We identified cohorts of individuals ≥ 18 years that met the algorithms' criteria for mild, moderate, and severe COVID‐19 at incident COVID‐19 diagnosis or positive SARS‐CoV‐2 test, and separately, at incident COVID‐19 treatment, from January 2022 through April 2023. We validated the algorithms via chart review of a random sample to calculate positive predictive values (PPVs) and 95% CIs.
Results
The algorithms identified 33 071 patients at COVID‐19 diagnosis or positive test; 26 985 mild (49 chart reviewed), 5180 moderate (55 reviewed), and 906 severe (56 reviewed). A total of 4512 patients were identified at COVID‐19 treatment; 3474 mild (56 reviewed), 848 moderate (60 reviewed), and 190 severe (46 reviewed). The PPVs (1) at COVID‐19 diagnosis or positive test were: mild 57% (95% CI: 43%–71%), moderate 58% (95% CI: 45%–71%), and severe 54% (95% CI: 41%–67%), and (2) at COVID‐19 treatment: mild 57% (95% CI: 44%–70%), moderate 70% (95% CI: 58%–82%) and severe 72% (95% CI: 59%–85%).
Conclusion
The algorithms had low‐to‐moderate performance in classifying COVID‐19 severity in ambulatory settings, depending on assessment at diagnosis or treatment. Researchers should consider the performance of the algorithm when using real‐world data to assess COVID‐19 severity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
- Harvard Medical School, Boston, Massachusetts, USA.
- Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
- Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.
- HealthPartners Institute, Bloomington, Minnesota, USA.
- Kaiser Permanente Colorado, Aurora CO, Colorado Permanente Medical Group, Denver, Colorado, USA.
ORCID-Profile: Gaia Pocobelli, Silvia Perez-Vilar
Förderung
- U.S. Food and Drug Administration
Zitieren
APA
Shinde, M. U., Shapiro, K., Hou, L., Coughlin, K., Madow, A. M., Shebl, F. M., Bright, P., Pocobelli, G., Ralston, J. D., Graham, V. F., Nolan, M. B., Binswanger, I. A., Pratt, N., Hua, W., Cocoros, N. M., & Perez-Vilar, S. (2026). Identifying COVID ‐19 Disease Severity in Real‐World Data: Implications for Medical Product Effectiveness Studies. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70363
Vancouver
Shinde MU, Shapiro K, Hou L, Coughlin K, Madow AM, Shebl FM, et al. Identifying COVID ‐19 Disease Severity in Real‐World Data: Implications for Medical Product Effectiveness Studies. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70363
BibTeX
@article{Shinde2026,
author = {Shinde, Mayura U and Shapiro, Katherine and Hou, Laura and Coughlin, Kevin and Madow, Aaron M and Shebl, Fatma M and Bright, Patricia and Pocobelli, Gaia and Ralston, James D and Graham, Vina F and Nolan, Margaret B and Binswanger, Ingrid A and Pratt, Natasha and Hua, Wei and Cocoros, Noelle M and Perez-Vilar, Silvia},
title = {Identifying COVID ‐19 Disease Severity in Real‐World Data: Implications for Medical Product Effectiveness Studies},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
doi = {10.1002/pds.70363}
}
EUVIMED